Relay Therapeutics to report Q3 2026 financial results and updates on Nov 4 after market close

Relay Therapeutics, a clinical-stage precision medicine company, will announce its third quarter 2026 financial results and corporate highlights on November 4, 2026, after U.S. market hours. The company is developing therapies for cancer and genetic diseases, with its lead drug zovegalisib in a Phase 3 trial for metastatic breast cancer and other genetic conditions. Investors will be watching for updates on clinical progress and financial performance. This report could impact perceptions of the company’s pipeline and future prospects.

Relay Therapeutics shares are trading near their 52-week high of $20.75, currently priced at $19.60 on Pluang as of Oct 29, 2026 03:21 WIB. This price marks a strong recovery from the 52-week low of $6.05, with a notable 1-day gain of 4.03%. Investors on Pluang typically hold RLAY stock for about 19 days, reflecting active interest around the company’s clinical developments and financial updates.